Gary Hammer

Gary D. Hammer, MD, PhD

Millie Schembechler Professor of Adrenal Cancer
Director of the Endocrine Oncology Program
Professor of Internal Medicine
Accepting new students?
Training and Identities:
Clinician and scientist (basic, translational and clinical research), academic and industry engagement
Research Interests:
adrenal homeostasis and disease

In the clinic, the lab and classroom - all are valued, welcomed, respected and desired equally - independent of the often historic hierarchical nature of medical and graduate training.

Research projects in his own laboratory are aimed at elucidating the mechanisms by which growth factor signaling and transcriptional programs initiate adrenal- specific growth and differentiation with an emphasis on dysregulated adrenocortical stem cells in development and cancer. Collaborative work with colleagues has led to the development of international cooperative groups, most recently the A5 (American Australian Asian Adrenal Alliance) that leverages collaboration to secure projects from Pharma and funding agencies to advance research and clinical care across the spectrum of adrenal diseases. He is a co- founder of two companies - MILLENDO and most recently VASARAGEN that focuses on rare endocrine diseases and the development of new biological-based therapies that target molecular defects in disease while sparing normal tissue.